Business
Rule 2.8 Announcement
EQT Fund Management S.à r.l. has announced that it does not intend to make an offer for Oxford Biomedica plc, following previous consideration of a possible bid. This statement, made under Rule 2.8 of the City Code on Takeovers and Mergers, means EQT and its concert parties are restricted from making a further offer for Oxford Biomedica for six months, unless certain conditions are met, such as agreement from Oxford Biomedica's board or a competing offer from a third party. Disclaimer*
About this update from Oxford Biomedica Plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") FOR IMMEDIATE RELEASE 25 February 2026 No intention to make an offer for Oxford Biomedica plc Further to the announcement on 14 January 2026 by Oxford Biomedica plc ("OXB") that EQT X EUR SCSp and EQT X USD SCSp each represented by its manager (gérant), EQT Fund Management S.à r.l. (collectively referred to as "EQT") was considering a possible offer for OXB, EQT today confirms that it is not intending to make an offer for OXB. EQT is appreciative of the engagement with OXB's board of directors and management team and would like to thank them for their time and consideration of this potential transaction. This announcement is made by EQT in accordance with Rule 2.8 of the Code. As a result of this announcement, EQT will, together with any party acting in concert with it, be bound by the restrictions in Rule 2.8 of Code. Under Note 2 on Rule 2.8 of the Code, EQT, and any party acting in concert with it, reserves the right to set the restrictions in Rule 2.8 aside in the following circumstances: a. with the agreement of the board of OXB; b. if a third party announces a firm intention to make an offer for OXB; c. if OXB announces a Rule 9 waiver (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse takeover (as defined in the Code); or d. if there has been a material change of circumstances (as determined by the Takeover Panel). Media Enquiries for EQT: FGS Global Faeth Birch / Chris Ryall / Sophia Johnston [email protected]
View stock analysis, news, and events for Oxford Biomedica Plc